LifeBiology is committed to building the entire industry chain of the in vitro diagnostic industry. It has made fruitful efforts in scientific research investment, international cooperation, talent introduction, etc., and has achieved a series of results.
(I) Continuously increase corporate R&D investment
General Secretary Xi Jinping pointed out in the report of the 20th National Congress of the Communist Party of China: Science and technology are the primary productive force, talents are the primary resource, and innovation is the primary driving force. Science and technology and innovation are inseparable from talents, the most important resource. In order to attract more outstanding talents to join, LifeBiology has invested a lot of scientific research funds and cooperated with many famous universities and research institutes at home and abroad, such as the University of Tokyo, the Chinese Academy of Sciences, Tianjin University, Shandong University, Ocean University of China, Qingdao University, etc., to establish expert workstations, joint laboratories, practical science popularization bases, etc., and has achieved initial results. For example, the Qingdao Guoke Bioengineering Technology Research Institute, jointly established with the Chinese Academy of Sciences, was rated as a provincial new R&D institution in 2021; the small-scale automated pathogenic microorganism nucleic acid library development and industrialization project jointly established with Shandong University and Qingdao University was approved as a key R&D project of Qingdao Science and Technology Plan in 2022. During the project period, it is expected to achieve a cumulative sales revenue of 12 million yuan and produce a number of high-quality scientific research results such as device product registration certificates, patents, and papers.  
(II) Continuously broaden international cooperation channels
In the process of accompanying Secretary Liu Jiayi on a visit to Japan in 2019, I had an accidental opportunity to pay attention to the application prospects of liquid chromatography tandem mass spectrometers in the precision medicine industry, and signed a cooperation intention with the Japanese side on the spot. After returning to China, we worked non-stop with the Japanese side, investigated the market, and formed an expert team to start R&D and industrialization of liquid chromatography tandem mass spectrometers, their spare parts, and supporting kits. The supporting test kit products have been launched in the provincial hospital and other tertiary hospitals. It is expected that the instrument product registration certificate and related intellectual property rights will be obtained and industrialized in the second half of 2023. At the same time, in view of the current situation that most antibody raw materials rely on imports, the in vitro diagnostic antibody reagent research and development and industrialization project jointly carried out by Lifei Biotechnology, the US PROMAB Company, Qingdao Traditional Chinese Medicine Hospital and other units has just been selected into the Qingdao Innovation Ecosystem Creation Special International Science and Technology Cooperation Plan. The project is expected to achieve the transformation of more than 300 antibody products, with an annual output value of more than 10 million yuan after reaching full production.      
(III) Continuously improve the upstream and downstream industrial chain
A single thread cannot make a line, and a single tree cannot make a forest. In the nearly 20 years of Lifei Biotechnology's entrepreneurship and development, we have achieved some results, but we have also taken many detours. In this process, we have been thinking about how to gather a group of medical device colleagues who share the same ideals as us for common development, establish a full upstream and downstream industrial chain of medical devices in Qingdao, increase innovative products, reduce homogeneous competition, reduce entrepreneurial costs, and improve the survival rate of start-up companies? In line with the idea of doing good for others, Lifei Bio invested in the construction of the 3C Innovation Service Platform for Medical Devices. With the business philosophy of "building a nest to attract phoenixes and building and sharing together", it provides a series of services for medical device companies from R&D and production, clinical trials, to product registration, commissioned production, supply chain and circulation warehousing, and strives to create a one-stop service solution from product incubation to pre-market guidance, and build an industrial gathering place that continuously gathers innovative resources.
Take Berger (Qingdao) Medical Technology Co., Ltd., which was introduced by the platform in 2022, as an example. In just half a year, it has achieved house purchase, decoration, acceptance, certification and production. The project fills the gap in the field of molecular diagnostic nucleic acid products in Qingdao and even Shandong Province. The 3C Innovation Service Platform also won the honorary titles of National Service-Oriented Manufacturing Demonstration Project and Qingdao Service-Oriented Manufacturing Demonstration Platform in 2022.
Of course, the achievement of the above achievements is inseparable from the strong support and help of the two-level governments of Qingdao City and the High-tech Zone. The "Qingdao Science and Technology Innovation Policy Micro Dictionary" issued by the Municipal Science and Technology Bureau and the "36 Science and Technology Innovation" and other policies that benefit enterprises issued by the High-tech Zone have all provided the most accurate and timely policy support in the key links of our development.
As time enters 2024, the intention of the cooperation project between Lifei Bio and Thermo Fisher Scientific has been initially reached, and the two parties have entered the final contract approval stage. This project cooperation not only enriches Lifei Bio's product line, but also recognizes the professionalism of our R&D team and service team. Thermo Fisher Scientific has nearly 10,000 products worldwide. This cooperation between Lifei Bio and Thermo Fisher Scientific has established a good start for more in-depth and diversified medical device projects to settle in Qingdao in the future.
As an emerging technology-based enterprise in Qingdao High-tech Zone, Lifei Bio plans to jointly launch the "Qingdao In Vitro Diagnostic Medical Device Innovation and Entrepreneurship Community" with Qingdao's industry leaders in the future. By establishing a community, it will drive the development of the city's in vitro diagnostic industry, take the market as the guide, effectively gather and optimize the allocation of resources, and provide support for the rapid development of Qingdao's biomedicine industry cluster. Here, I sincerely hope that the Municipal Science and Technology Bureau and all the leaders, experts and colleagues present here can give strong support and help.
The road ahead is long and difficult, but if you keep going, you will reach your destination. If you keep going, you will have a promising future. Lifei Bio will also live up to the responsibilities entrusted by the times, take "through advanced medical diagnostic technology, products and services, let more people enjoy healthy life" as its mission, drive by technological innovation, and make greater contributions to the development of the medical device industry in our city!